Comparative Pharmacology
Head-to-head clinical analysis: MYCHEL S versus VIBATIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCHEL S versus VIBATIV.
MYCHEL-S vs VIBATIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Lipoglycopeptide antibiotic that inhibits cell wall synthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation. Also disrupts membrane potential and increases membrane permeability.
200 mg orally every 12 hours for 14 days
10 mg/kg intravenously once every 24 hours, infused over 60 minutes for 7 to 14 days.
None Documented
None Documented
3-4 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is approximately 177 hours (7.4 days), supporting once-daily dosing.
Renal: 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Primarily renal excretion as unchanged drug (approximately 93% of dose recovered in urine; <5% in feces).
Category C
Category C
Antibiotic
Antibiotic